Borna disease virus (BDV) is a negative‑sense, single‑stranded RNA virus that belongs to the family Bornaviridae and the genus Mammalian 2 orthobornavirus. It is the causative agent of Borna disease, a neurological disorder primarily affecting horses and sheep, and has been implicated—though not conclusively—in certain human psychiatric conditions.
Taxonomy and Structure
- Order: Mononegavirales
- Family: Bornaviridae
- Genus: Mammalian 2 orthobornavirus (formerly Bornavirus)
- Species: Mammalian 2 orthobornavirus (commonly referred to as Borna disease virus)
The virion is enveloped, spherical to pleomorphic, and measures approximately 100–130 nm in diameter. The viral genome is about 8.9 kb in length and encodes six major proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), large polymerase protein (L), and the X protein, which modulates host immune responses.
Epidemiology
BDV is endemic in parts of central Europe, with natural reservoirs identified in wild and domestic birds, particularly the blackbird (Turdus merula) and the song thrush (Turdus philomelos). Transmission to mammals occurs via direct contact with contaminated secretions, particularly saliva and urine, or indirectly through environmental exposure. The virus is highly neurotropic, establishing persistent infections within the central nervous system of its hosts.
Pathogenesis and Clinical Manifestations
In susceptible mammals, BDV infection can cause:
- Acute encephalitis: characterized by behavioral changes, motor dysfunction, ataxia, and seizures.
- Chronic disease: marked by progressive neurodegeneration, weight loss, and eventual death.
In horses and sheep, disease onset typically follows a stressor such as transportation, weaning, or parturition. The incubation period ranges from weeks to months. Histopathologically, BDV infection is associated with non‑suppurative inflammation, neuronal loss, and gliosis.
Human Associations
Several sero‑epidemiological studies have detected antibodies against BDV in subsets of patients with mood disorders, schizophrenia, and other psychiatric conditions. However, causality remains unproven, and meta‑analyses have highlighted methodological limitations and inconsistencies across studies. Consequently, the role of BDV in human disease is uncertain and regarded as unproven by major health organizations.
Diagnosis
- Molecular detection: reverse transcription polymerase chain reaction (RT‑PCR) targeting conserved genomic regions (e.g., N or L genes).
- Serology: enzyme‑linked immunosorbent assay (ELISA) for BDV‑specific IgG/IgM antibodies.
- Histopathology: immunohistochemical staining for BDV antigens in brain tissue.
Treatment and Prevention
No specific antiviral therapy is approved for BDV infection in animals. Management focuses on supportive care and, in some cases, the use of immunomodulatory agents such as corticosteroids. Preventive measures include:
- Biosecurity: limiting contact between susceptible mammals and wild bird populations.
- Environmental hygiene: regular cleaning of stables and avoidance of contamination with bird droppings.
Vaccines against BDV are not commercially available.
History
The disease was first described in the early 20th century in the town of Borna, Germany, after which it was named. Initial experimental work demonstrated that the disease could be transmitted experimentally to laboratory animals, leading to the identification of the underlying viral agent in the 1970s.
Research Significance
BDV serves as a model for studying persistent, non‑lytic viral infections of the central nervous system. Its ability to establish long‑term latency without overt cytopathic effect provides insights into viral evasion of host immunity and mechanisms of neuroinflammation. The virus has also been employed in vector systems for neuronal gene delivery due to its natural tropism for neurons.
